Total Payments
$11,235
2024 Payments
$4,185
Companies
66
Transactions
600
Medicare Patients
2,756
Medicare Billing
$698,049
Payment Breakdown by Category
Food & Beverage$10,680 (95.1%)
Education$554.60 (4.9%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $10,680 | 587 | 95.1% |
| Education | $554.60 | 13 | 4.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $897.75 | 53 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $849.93 | 41 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $751.89 | 46 | $0 (2024) |
| Incyte Corporation | $625.51 | 20 | $0 (2024) |
| Genentech USA, Inc. | $559.37 | 37 | $0 (2024) |
| Janssen Biotech, Inc. | $548.56 | 27 | $0 (2024) |
| PFIZER INC. | $547.54 | 47 | $0 (2024) |
| Gilead Sciences, Inc. | $536.11 | 27 | $0 (2024) |
| Seagen Inc. | $442.70 | 27 | $0 (2023) |
| Merck Sharp & Dohme LLC | $410.75 | 23 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,185 | 209 | Novartis Pharmaceuticals Corporation ($416.50) |
| 2023 | $3,781 | 182 | Novartis Pharmaceuticals Corporation ($296.03) |
| 2022 | $840.95 | 50 | Seagen Inc. ($134.14) |
| 2021 | $839.42 | 42 | Incyte Corporation ($238.71) |
| 2020 | $293.53 | 20 | E.R. Squibb & Sons, L.L.C. ($175.41) |
| 2019 | $357.44 | 21 | Seattle Genetics, Inc. ($47.00) |
| 2018 | $578.09 | 51 | Seattle Genetics, Inc. ($131.17) |
| 2017 | $359.52 | 25 | Genentech USA, Inc. ($56.76) |
All Payment Transactions
600 individual payment records from CMS Open Payments — Page 1 of 24
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $31.50 | General |
| Category: Oncology | ||||||
| 12/20/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $22.21 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $12.88 | General |
| 12/18/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $11.82 | General |
| Category: Hematology | ||||||
| 12/15/2024 | Incyte Corporation | MONJUVI (Drug), PEMAZYRE | Food and Beverage | Cash or cash equivalent | $17.69 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $27.25 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $9.87 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 12/06/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $29.04 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $24.30 | General |
| Category: Oncology | ||||||
| 12/05/2024 | ARRAY BIOPHARMA INC | XALKORI (Drug), LORBRENA, BRAFTOVI | Food and Beverage | In-kind items and services | $20.36 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $15.58 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $14.89 | General |
| Category: ONCOLOGY | ||||||
| 11/25/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $22.06 | General |
| Category: Oncology / Rare Diseases | ||||||
| 11/22/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $17.53 | General |
| Category: Oncology | ||||||
| 11/20/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $24.66 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Celltrion USA Inc. | VEGZELMA (Biological) | Food and Beverage | In-kind items and services | $15.44 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $20.79 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/19/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $20.79 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/18/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $13.22 | General |
| Category: Hematology | ||||||
| 11/15/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $1.51 | General |
| 11/14/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $18.60 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $18.96 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $1.64 | General |
| 11/12/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $26.46 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $7.83 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 25 | 1,090 | 19,647 | $2.5M | $312,419 |
| 2022 | 6 | 555 | 1,017 | $283,632 | $93,544 |
| 2021 | 6 | 603 | 1,316 | $347,148 | $152,522 |
| 2020 | 6 | 508 | 1,317 | $294,755 | $139,564 |
Total Patients
2,756
Total Services
23,297
Medicare Billing
$698,049
Procedure Codes
43
All Medicare Procedures & Services
43 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 24 | 3,660 | $260,280 | $68,196 | 26.2% |
| Q5108 | Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | Office | 2023 | 17 | 600 | $563,400 | $57,273 | 10.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 207 | 432 | $96,768 | $40,502 | 41.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 77 | 302 | $207,172 | $28,887 | 13.9% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 31 | 213 | $838,794 | $28,162 | 3.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 100 | 202 | $60,802 | $26,484 | 43.6% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 24 | 10,010 | $90,090 | $13,738 | 15.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 122 | 190 | $28,120 | $11,821 | 42.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 67 | 67 | $28,944 | $11,236 | 38.8% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 58 | 430 | $45,150 | $4,970 | 11.0% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 29 | 92 | $30,728 | $4,410 | 14.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 22 | 59 | $17,936 | $2,766 | 15.4% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 23 | 112 | $17,472 | $2,359 | 13.5% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 18 | 54 | $15,174 | $2,230 | 14.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 15 | 15 | $6,180 | $2,055 | 33.3% |
| 99195 | Drawing of blood for a medical problem | Office | 2023 | 11 | 27 | $6,777 | $1,843 | 27.2% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 36 | 77 | $10,857 | $1,817 | 16.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 59 | 164 | $15,252 | $1,753 | 11.5% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 28 | 980 | $119,560 | $810.62 | 0.7% |
| 96523 | Irrigation of implanted venous access drug delivery device | Office | 2023 | 15 | 23 | $2,553 | $414.04 | 16.2% |
| 96361 | Infusion into a vein for hydration, each additional hour | Office | 2023 | 15 | 29 | $2,117 | $279.08 | 13.2% |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | Office | 2023 | 19 | 470 | $11,750 | $141.59 | 1.2% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 40 | 1,332 | $1,332 | $126.63 | 9.5% |
| J7030 | Infusion, normal saline solution , 1000 cc | Office | 2023 | 14 | 49 | $931.00 | $98.87 | 10.6% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 19 | 58 | $406.00 | $46.34 | 11.4% |
About Dr. Scott Herbert, MD
Dr. Scott Herbert, MD is a Hematology healthcare provider based in Albuquerque, New Mexico. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1548340870.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Scott Herbert, MD has received a total of $11,235 in payments from pharmaceutical and medical device companies, with $4,185 received in 2024. These payments were reported across 600 transactions from 66 companies. The most common payment nature is "Food and Beverage" ($10,680).
As a Medicare-enrolled provider, Herbert has provided services to 2,756 Medicare beneficiaries, totaling 23,297 services with total Medicare billing of $698,049. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Hematology & Oncology
- Location Albuquerque, NM
- Active Since 10/17/2006
- Last Updated 10/29/2025
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1548340870
Products in Payments
- KEYTRUDA (Biological) $401.17
- OPDIVO (Biological) $387.10
- ENHERTU (Biological) $348.20
- ADCETRIS (Biological) $337.59
- MONJUVI (Drug) $292.73
- REBLOZYL (Biological) $289.82
- Trodelvy (Drug) $283.23
- Lenvima (Drug) $273.36
- KISQALI (Drug) $263.11
- CABOMETYX (Drug) $253.90
- JAKAFI (Drug) $242.79
- XTANDI (Drug) $224.68
- Yescarta (Drug) $197.37
- PLUVICTO (Drug) $191.42
- PADCEV (Biological) $184.29
- BRUKINSA (Drug) $169.17
- LUTATHERA (Drug) $165.01
- IMFINZI (Biological) $147.43
- AYVAKIT (Drug) $139.66
- Alecensa (Biological) $131.73
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in Albuquerque
Hank Hanna, Md, MD
Hematology — Payments: $1.1M
Hematology $1.1M
George Atweh, Md, MD
Hematology — Payments: $51,885
Hematology $51,885
Dr. Marian Rollins-Raval, M.d. M.p.h, M.D. M.P.H
Hematology — Payments: $31,075
Hematology $31,075
Leslie Andritsos, Md, MD
Hematology — Payments: $28,051
Hematology $28,051
Dr. Ateefa Chaudhury, M.d, M.D
Hematology — Payments: $15,336
Hematology $15,336
Dr. Ala Ebaid, Md, MD
Hematology — Payments: $8,040
Hematology $8,040